文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

优化氯胺酮使用以减少因肿瘤指征行乳房切除术女性慢性术后疼痛:KALPAS多中心随机对照试验研究方案

Optimizing the use of ketamine to reduce chronic postsurgical pain in women undergoing mastectomy for oncologic indication: study protocol for the KALPAS multicenter randomized controlled trial.
PubMed 文献 · Trials · 2024-01-19

KALPAS是一项3期多中心随机安慰剂对照双盲试验,比较围术期持续氯胺酮输注、麻醉后监护室单次氯胺酮与安慰剂对乳房切除术后疼痛综合征的预防效果,主要结局为术后3个月手术部位疼痛,随访1年。

要点

  • 乳房切除术后3个月有25-60%患者报告疼痛,即乳房切除术后疼痛综合征。
  • 近期研究显示每10例患者中1例在治愈性手术后至少3个月继续使用阿片类药物。
  • 标准围术期多模式镇痛对慢性术后疼痛预防仅中度有效,急需干预措施。

核心结论

  • 该研究旨在比较围术期持续氯胺酮输注、麻醉后监护室单次氯胺酮与安慰剂对乳房切除术后疼痛综合征的预防效果,有望对围术期疼痛管理产生重大影响并助力应对阿片类药物流行。
  • 氯胺酮通过靶向急性疼痛和改善围术期情绪,可能预防慢性术后疼痛的发生。

研究设计与样本

  • KALPAS是一项3期、多中心、随机、安慰剂对照、双盲试验,比较围术期持续氯胺酮输注、麻醉后监护室单次氯胺酮与安慰剂对乳房切除术后疼痛综合征的效果。
  • 参与者术后随访1年,主要结局为指数手术后3个月手术部位疼痛,采用简明疼痛量表简版疼痛严重程度子量表评估。
  • 试验注册于ClinicalTrials.gov,编号NCT05037123,注册日期2021年9月8日。

主要发现

  • 乳房切除术后3个月有25-60%的患者报告疼痛,即乳房切除术后疼痛综合征,干扰功能、恢复和辅助治疗依从性。
  • 近期研究显示每10例患者中1例在治愈性手术后至少3个月继续使用阿片类药物。
  • 过去10年女性阿片类药物依赖增长率超过男性。
  • 标准围术期多模式镇痛对慢性术后疼痛的预防仅中度有效。
  • 氯胺酮在急性术后期间已知可改善疼痛并减少阿片类药物使用,并在焦虑和抑郁研究中显示可控制情绪。

临床怎么用

  • 作者认为,通过靶向急性疼痛和改善围术期情绪,氯胺酮可能预防慢性术后疼痛的发生。
  • 该研究为NIH帮助终结成瘾长期(HEAL)计划的一部分,旨在应对阿片类药物公共卫生危机。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mastectomies are commonly performed and strongly associated with chronic postsurgical pain (CPSP), more specifically termed postmastectomy pain syndrome (PMPS), with 25-60% of patients reporting pain 3 months after surgery. PMPS interferes with function, recovery, and compliance with adjuvant therapy. Importantly, it is associated with chronic opioid use, as a recent study showed that 1 in 10 patients continue to use opioids at least 3 months after curative surgery. The majority of PMPS patients are women, and, over the past 10 years, women have outpaced men in the rate of growth in opioid dependence. Standard perioperative multimodal analgesia is only modestly effective in prevention of CPSP. Thus, interventions to reduce CPSP and PMPS are urgently needed. Ketamine is well known to improve pain and reduce opioid use in the acute postoperative period. Additionally, ketamine has been shown to control mood in studies of anxiety and depression. By targeting acute pain and improving mood in the perioperative period, ketamine may be able to prevent the development of CPSP. METHODS: Ketamine analgesia for long-lasting pain relief after surgery (KALPAS) is a phase 3, multicenter, randomized, placebo-controlled, double-blind trial to study the effectiveness of ketamine in reducing PMPS. The study compares continuous perioperative ketamine infusion vs single-dose ketamine in the postanesthesia care unit vs placebo for reducing PMPS. Participants are followed for 1 year after surgery. The primary outcome is pain at the surgical site at 3 months after the index surgery as assessed with the Brief Pain Inventory-short form pain severity subscale. DISCUSSION: This project is part of the NIH Helping to End Addiction Long-term (HEAL) Initiative, a nationwide effort to address the opioid public health crisis. This study can substantially impact perioperative pain management and can contribute significantly to combatting the opioid epidemic. TRIAL REGISTRATION: ClinicalTrials.gov NCT05037123. Registered on September 8, 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wang J, Doan LV, Axelrod D, et al. Optimizing the use of ketamine to reduce chronic postsurgical pain in women undergoing mastectomy for oncologic indication: study protocol for the KALPAS multicenter randomized controlled trial. Trials. 2024. PMID: 38243266. doi:10.1186/s13063-023-07884-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。